Viatris Agrees to Acquire Pacira BioSciences in $1.65 Billion Deal
12:02 PM EDT, 10/08/2026 (MT Newswires) -- Viatris (VTRS) will acquire Pacira BioSciences (PCRX) in an all-cash deal worth roughly $1.65 billion, as the healthcare company looks to strengthen its non-opioid pain management portfolio. Viatris will launch a tender offer for all of Pacira's shares at $36.50 apiece, the companies said in a joint statement on Thursday. Pacira's stock surged 44% in Thursday trade, while Viatris declined 1.7%. The acquisition will give Viatris access to two Pacira's patent-protected products in the US, Exparel and Zilretta. "The addition of Exparel, for acute postsurgical pain, and Zilretta, for osteoarthritis knee pain, are synergistic with our fast-acting meloxicam market opportunity and position us as a leader in non-opioid pain management therapies," Viatris Chief Executive Scott Smith said in the statement. Viatris intends to expand the two products' reach across certain markets. Pacira recorded about $746 million in revenue during the 12 months ended June 30, according to the companies. "Pacira also brings Viatris additional US innovative commercial, market access, medical affairs and global (research and development) capabilities," Smith said. The deal is expected to complete by the end of the year, following which Pacira will no longer trade on the Nasdaq Global Select Market. "This transaction accelerates our path to sustained revenue and earnings growth and adds an innovative development pipeline in certain high-value, specialty-driven therapeutic areas with a high unmet need," Smith said. Interim CFO Paul Campbell said the deal is expected to be immediately accretive to Viatris' financial guidance metrics. In August, Pacira said it expected 2026 revenue of $735 million to $760 million, with Exparel generating sales between $600 million and $620 million. The current consensus on FactSet is for the firm to record overall topline of $754.4 million for the current year. "We are confident that Viatris' shared vision, substantial resources, and global scale will accelerate the impa
12:02 PM EDT, 10/08/2026 (MT Newswires) -- Viatris (VTRS) will acquire Pacira BioSciences (PCRX) in an all-cash deal worth roughly $1.65 billion, as the healthcare company looks to strengthen its non-opioid pain management portfolio. Viatris will launch a tender offer for all of Pacira's shares at $36.50 apiece, the companies said in a joint statement on Thursday. Pacira's stock surged 44% in Thursday trade, while Viatris declined 1.7%. The acquisition will give Viatris access to two Pacira's patent-protected products in the US, Exparel and Zilretta. "The addition of Exparel, for acute postsurgical pain, and Zilretta, for osteoarthritis knee pain, are synergistic with our fast-acting meloxicam market opportunity and position us as a leader in non-opioid pain management therapies," Viatris Chief Executive Scott Smith said in the statement. Viatris intends to expand the two products' reach across certain markets. Pacira recorded about $746 million in revenue during the 12 months ended June 30, according to the companies. "Pacira also brings Viatris additional US innovative commercial, market access, medical affairs and global (research and development) capabilities," Smith said. The deal is expected to complete by the end of the year, following which Pacira will no longer trade on the Nasdaq Global Select Market. "This transaction accelerates our path to sustained revenue and earnings growth and adds an innovative development pipeline in certain high-value, specialty-driven therapeutic areas with a high unmet need," Smith said. Interim CFO Paul Campbell said the deal is expected to be immediately accretive to Viatris' financial guidance metrics. In August, Pacira said it expected 2026 revenue of $735 million to $760 million, with Exparel generating sales between $600 million and $620 million. The current consensus on FactSet is for the firm to record overall topline of $754.4 million for the current year. "We are confident that Viatris' shared vision, substantial resources, and global scale will accelerate the impact of our mission and help bring our transformative therapies to even more patients," according to Pacira CEO Frank Lee. Viatris raised the mid-point of its full-year earnings outlook in August as second-quarter results rose year on year. It will report third-quarter results Nov. 5. In October 2025, the company completed its acquisition of Aculys Pharma, including rights to develop and commercialize central nervous system therapy assets in Japan and select Asia-Pacific markets. Last month, Zymeworks (ZYME) completed its acquisition of Yupelri-maker Theravance Biopharma. Yupelri is a prescription medicine used to treat chronic obstructive pulmonary disease and chronic lung disease. In April, Sun Pharmaceutical Industries agreed to acquire women's health company Organon (OGN) for $14 per share in cash, representing an enterprise value of $11.75 billion. The deal is expected to close in early 2027. Price: 17.14, Change: -0.35, Percent Change: -2.00
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now！
MT newswire2026/10/08 16:02
